The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

StatusUnknown
PhasePhase 2
Started

Record status This record was last updated September 25, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v8
  3. Primary completion date: Dec 31, 2023 to Dec 31, 2024
    • Study completion date: Jun 30, 2024 to Jun 30, 2025
    v7
  4. Re-verified, no change to tracked fieldsv6
  5. Primary completion date: Jun 30, 2023 to Dec 31, 2023
    • Study completion date: Jun 30, 2023 to Jun 30, 2024
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 1 to 3v4
  2. Primary completion date: May 1, 2022 to Jun 30, 2023
    • Study completion date: Aug 31, 2022 to Jun 30, 2023
    v3
  3. Eligibility criteria expanded, about 22 wordsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, single-arm study to evaluate the safety and efficacy of Ibrutinib in subjects with refractory/relapsed autoimmune hemolytic anemia.
Trial Details
NCT Number NCT04398459
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions
(from sponsor)		 Refractory/Relapsed Autoimmune Hemolytic Anemia
Related terms Anemia, Hemolytic, Autoimmune
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov